Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCRgenes are associated with breast cancer: a case-control study

Abstract

BackgroundThe procoagulant state in cancer increases the thrombotic risk, but also supports tumor progression. To investigate the molecular mechanisms controlling cancer and hemostasis, we conducted a case-control study of genotypic and phenotypic variables of the tissue factor (TF) pathway of coagulation in breast cancer.Methods366 breast cancer patients and 307 controls were genotyped for SNPs (n = 41) in the F2, F3 (TF), F5, F7, F10, TFPI and EPCR genes, and assayed for plasma coagulation markers (thrombin generation, activated protein C (APC) resistance, D-dimer, antithrombin, protein C, protein S, and TF pathway inhibitor (TFPI)). Associations with breast cancer were evaluated using logistic regression to obtain odds ratios (ORs) and 95% confidence intervals (CIs), or the chi-square test.ResultsFour SNPs in F5 (rs12120605, rs6427202, rs9332542 and rs6427199), one in F10 (rs3093261), and one in EPCR (rs2069948) were associated with breast cancer. EPCR rs2069948 was associated with estrogen receptor (ER) and progesterone receptor (PR) positivity, while the SNPs in F5 appeared to follow hormone receptor negative and triple negative patients. The prothrombotic polymorphisms factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) were not associated with breast cancer. High APC resistance was associated with breast cancer in both factor V Leiden non-carriers (OR 6.5, 95% CI 4.1-10.4) and carriers (OR 38.3, 95% CI 6.2-236.6). The thrombin parameters short lag times (OR 5.8, 95% CI 3.7-9.2), short times to peak thrombin (OR 7.1, 95% CI 4.4-11.3), and high thrombin peak (OR 6.1, 95% CI 3.9-9.5) predicted presence of breast cancer, and high D-dimer also associated with breast cancer (OR 2.0, 95% CI 1.3-3.3). Among the coagulation inhibitors, low levels of antithrombin associated with breast cancer (OR 5.7, 95% CI 3.6-9.0). The increased coagulability was not explained by the breast cancer associated SNPs, and was unaffected by ER, PR and triple negative status.ConclusionsA procoagulant phenotype was found in the breast cancer patients. Novel associations with SNPs in F5, F10 and EPCR to breast cancer susceptibility were demonstrated, and the SNPs in F5 were confined to hormone receptor negative and triple negative patients. The study supports the importance of developing new therapeutic strategies targeting coagulation processes in cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-845) contains supplementary material, which is available to authorized users.

Serum levels of inflammation‐related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers

“…S1 a –S1 c ) and endothelial cell protein C receptor (ePCR) levels (Figs. d – f ), a gene associated with risk of breast cancer were lower for responders throughout treatment.…”

Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer

“…A couple of previous studies have reported the F5 gene as a risk marker of cancer. For instance, Vossen et al demonstrated that the F5 gene polymorphism is associated with the susceptibility to colorectal cancer in a German population compared with controls, and similar results were obtained for breast cancer [22,23]. However, other researchers found that F5 is not a risk factor for cancers such as gynaecological and oral cancers and gliomas [24][25][26][27][28].…”

Targeting clotting proteins in cancer therapy – progress and challenges

“…Genetic polymorphisms associated with breast cancer furthermore show that traditional prothrombotic risk factors are not the sole determinant for tumor progression and that additional hemostatic components, i.e. FX and the endothelial protein C receptor (EPCR), may be contributing to the development of cancer (43). …”